clopidogrel has been researched along with No-Reflow Phenomenon in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aitmokhtar, O; Azaza, A; Azzouz, A; Benamara, S; Benathmane, T; Benkhedda, S; Bonello, L; Bouzid, A; Hamza, O; Harbi, F; Kara, M; Monsuez, JJ; Paganelli, F; Saidane, M; Seddiki, S; Sik, A | 1 |
| Gasior, M; Hawranek, M; Kaczmarski, J; Kuliczkowski, W; Laszowska, A; Polonski, L; Pres, D; Serebruany, VL; Szewczyk, M; Tajstra, M; Zeglen, S | 1 |
| Dong, M; Li, L; Mu, N; Ren, F; Tan, J; Zhang, C; Zhang, X | 1 |
| Barbato, E; Bartunek, J; De Bruyne, B; Heyndrickx, GR; Mangiacapra, F; Muller, O; Ntalianis, A; Trana, C; Vanderheyden, M; Wijns, W | 1 |
| Aksu, H; Bozbeyoglu, E; Nurkalem, Z; Satilmis, S; Yildirimturk, O | 1 |
| Kompatscher, P; Riml, S; Wallner, H | 1 |
6 other study(ies) available for clopidogrel and No-Reflow Phenomenon
| Article | Year |
|---|---|
Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Topics: Aged; Area Under Curve; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Coronary Circulation; Drug Resistance; Female; Humans; Male; Microcirculation; Middle Aged; Multivariate Analysis; No-Reflow Phenomenon; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; ROC Curve; ST Elevation Myocardial Infarction; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Aspirin 'resistance': impact on no-reflow, platelet and inflammatory biomarkers in diabetics after ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Diabetes Complications; Drug Resistance; Female; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2015 |
Increased Platelet-leukocyte Aggregates Are Associated With Myocardial No-reflow in Patients With ST Elevation Myocardial Infarction.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Electrocardiography; Female; Flow Cytometry; Humans; Leukocytes; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Retrospective Studies; Ticlopidine | 2016 |
Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Female; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Registries; Survival Rate; Ticlopidine; Treatment Outcome | 2010 |
Impact of clopidogrel resistance on ST-segment resolution and no-reflow in acute myocardial infarction with ST-elevation patients treated with a primary percutaneous coronary intervention.
Topics: Clopidogrel; Coronary Angiography; Coronary Circulation; Drug Resistance; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recovery of Function; Ticlopidine; Treatment Outcome | 2012 |
Friend or foe? Discussion about dual platelet inhibition as a salvage procedure from imminent flap failure.
Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Mammaplasty; Middle Aged; No-Reflow Phenomenon; Platelet Aggregation Inhibitors; Postoperative Complications; Salvage Therapy; Surgical Flaps; Ticlopidine | 2013 |